Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Share on facebook
Share on twitter
Share on linkedin

November 10, 2012: BioAegis Therapeutics Exercises Option for Exclusive License to Recombinant Human Plasma Gelsolin from Brigham and Women’s Hospital

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2012) Pursuant to the terms of the agreement with the Brigham and Women’s Hospital previously announced on May 11, 2011, BioAegis Therapeutics elected to exercise its option into an exclusive license to recombinant human plasma gelsolin technology.